NCT02589795View on ClinicalTrials.gov

Safety and Immunogenicity of HIV DNA-C CN54ENV and Recombinant HIV CN54gp140 Vaccines in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 11, 2016

Primary Completion Date

December 22, 2017

Study Completion Date

December 22, 2017

Conditions
HIV
Interventions
BIOLOGICAL

DNA-C CN54ENV

DNA plasmid containing the Clade C gp140 envelope gene from HIV-1 isolate CN54

BIOLOGICAL

CN54gp140

Recombinant protein expressed from the Clade C gp140 envelope gene from HIV-1 isolate CN54

DEVICE

Trigrid Delivery System - Intramuscular

Electroporation

DEVICE

Trigrid Delivery System - Intradermal

Electroporation

Trial Locations (1)

W12 0HS

NIHR/Wellcome Trust Imperial Clinical Research Facility, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London

Sponsors

Collaborators (1)

Medical Research Council
All Listed Sponsors
collaborator

Medical Research Council

OTHER_GOV

lead

Imperial College London

OTHER

NCT02589795 - Safety and Immunogenicity of HIV DNA-C CN54ENV and Recombinant HIV CN54gp140 Vaccines in Healthy Volunteers | Biotech Hunter | Biotech Hunter